NSE · SANOFI
Sanofi India Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹492 Cr with net profit ₹117 Cr — a 23.73% net margin, versus 19.08% the period before.
Shareholding
As of 2026-09-30
- Promoter60.4%
- Public14.47%
- FII5.73%
- DII19.4%
80,089 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.73× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Multinational · ranked #5 of 6 by market cap · medians across 5 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Abbott India Limited | ₹55,981 Cr | 34.67 | 11.72 | 38.71% | 22.96% |
| Glaxosmithkline Pharmaceuticals Ltd. | ₹42,772 Cr | 37.74 | 22.74 | 60.95% | 27.57% |
| Pfizer Ltd. | ₹17,640 Cr | 22.18 | 4.02 | 19.6% | 32.38% |
| Sanofi Consumer Healthcare India Ltd. | ₹7,877 Cr | 28.16 | 22.67 | 76.46% | 28.57% |
| Sanofi India Limited(this company) | ₹7,561 Cr | 20.74 | 9.15 | 39.2% | 20.01% |
| Evonile Pharma Limited | ₹4,342 Cr | 67.55 | 5.64 | 8.33% | -1.19% |
AI analysis
AI-generated · google/gemini-2.5-flashSanofi India Limited has a market capitalization of Rs 7863 Cr. The company reported a revenue of Rs 1857.1 Cr and an EPS of 142.04. Its 52-week high is Rs 5955 and the 52-week low is Rs 3054.
Positives
- +The company has a low debt-to-equity ratio of 0.02.
- +Return on Capital Employed (ROCE) is high at 52.41%.
- +Return on Equity (ROE) is 40.6%.
Negatives
- −Revenue decreased from Rs 510.8 Cr in Mar 2024 to Rs 463.5 Cr in Jun 2024.
- −Net profit decreased from Rs 136.6 Cr in Mar 2024 to Rs 103.2 Cr in Jun 2024.
- −Promoter shareholding in June 2026 is 60.3961, compared to higher figures in prior periods (no prior data in JSON).
Financial performance
In the latest reported annual performance for Mar 2026, the company recorded a revenue of Rs 472.3 Cr and a net profit of Rs 102.6 Cr. Over the preceding four quarters, from Mar 2025 to Dec 2025, annual revenue reached Rs 1857.1 Cr. Quarterly revenues have varied, with Rs 514.9 Cr in Dec 2024 and Rs 524 Cr in Sept 2024. Quarterly net profit stood at Rs 91.3 Cr in Dec 2024.
Profitability & returns
The company’s Return on Equity (ROE) is 40.6% and Return on Capital Employed (ROCE) is 52.41%. The Earnings Per Share (EPS) is reported at 142.04. Over the annual periods up to Mar 2026, the net profit for Mar 2026 was Rs 102.6 Cr, following Rs 61.7 Cr in Dec 2025 and Rs 76 Cr in Sept 2025.
Balance sheet
The company maintains a low debt-to-equity ratio of 0.02. The book value per share is Rs 325.74. The company has no reported pledges against promoter holdings.
Ownership & pledges
Public shareholders account for 14.0449% of the shares. There are no shares pledged by the promoters.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.